奥本海默认为诺如疫苗市场极具吸引力，价值约为50亿至100亿美元。奥本海默补充说，它并未将最近HilleVax(HLVX.US)诺如病毒肌肉注射疫苗的开发遭遇挫折视为对Vaxart项目不利的信号。Oberonheimer's first coverage of Vaxart (VXRT.US) gives it an "outperform" rating, with a target price of $4, outperforming the large cap.
Zhongtong Finance APP learned that Oberonheimer's first coverage of Vaxart (VXRT.US), gave it a "beat the large cap" rating, with a target price of $4, as the company focuses on oral vaccines.
The investment bank is optimistic about Vaxart's differentiated oral vaccine platform, particularly its candidate vaccines for norovirus and COVID-19. Oberonheimer pointed out that oral vaccines can provide better solutions for infectious diseases such as noroviruses.
Oberonheimer assumes the norovirus vaccine market is highly attractive with a value of around $5 billion to $10 billion. Oberonheimer also added that it does not regard the recent development setback of HilleVax (HLVX.US) norovirus intramuscular injection vaccine as a negative signal for the Vaxart project.
As of Thursday's close, Vaxart rose 25.66% to $0.743.
